Nanomix Completes Reverse Merger with Boston Therapeutics; $8.4M Convertible Financing

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

Lomond Therapeutics Completes Reverse Merger with Venetian-1 and Raises $44M

November 4, 2024

Biotechnology

Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.

Bruker Corporation Acquires NanoString Technologies Business

May 6, 2024

Medical Devices

Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.

Element Materials Technology Acquires Nanosyn

October 11, 2021

Pharmaceuticals

Element Materials Technology acquired Nanosyn, a San Francisco Bay Area-based contract development and manufacturing organization (CDMO) focused on drug discovery and small-batch API manufacturing, to strengthen Element’s pharmaceuticals and biopharmaceutical services in North America. Nanosyn operates three Bay Area facilities and has a team of more than 75 scientists, and the deal expands Element’s end-to-end life sciences capabilities from discovery through clinical development and regulatory support.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.